blank.png

FAQs

Frequently Asked Questions about CAPP

 

How do I apply for CAPP?

see answer

You can apply for any one of the three streams by simply filling out a short application form (20 minutes) on our website. You can also click on the "APPLY NOW" button at the bottom of this page after you review all the FAQs.


Will my information be shared with third parties?

see answer

No, all your information will remain strictly confidential and will only be used for selection purposes.


Is there a geographic preference for applicants?

see answer

No, we believe that science has no boundary - we therefore invite academic researchers from all countries to participate in CAPP. In 2018, we have received applications from the United States, Canada, UK, Australia, and China.


I have more than 3 molecules that I want to examine through Ligand Express®, can I submit more?

see answer

Only up to 3 molecules will be accepted for each application.


Can I submit more than one application?

see answer

Yes, you can submit multiple applications, provided that each application has a distinct research question.


Is there any opportunity to publish novel findings generated through CAPP?

see answer

Absolutely. We have a proven record of helping academic researchers publish articles in peer-reviewed journals (see examples here). We value close collaboration with our academic partners and encourage sharing scientific findings with the academic community.


How are the finalists selected?

see answer

Selection will be based on the soundness of your research question and the impact of your projects. The query molecules have to have a viable synthetic path or preferably have been already synthesized so that scientists are able to perform subsequent bioassays.


What's the IP ownership for novel findings discovered through the CAPP collaboration?

see answer

For LEAP, any IP around the compound is retained by the PI/Institution and not by Cyclica.

For DANCE, where novel chemical enetities are designed by Cyclica's Ligand Design™ platform, the IP of chemical structure will be shared between the academic partner and Cyclica for future research and/or commercialization.